4D Molecular Therapeutics Inc FDMT:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 06/02/26 EDT
9.53
+0.26 (+2.80%)
+0.26 (+2.80%)Volume
936,333
52 week range
3.68 - 12.34
- Open9.28
- Day High9.66
- Day Low8.97
- Prev Close9.53
- 52 Week High12.34
- 52 Week High Date10/28/25
- 52 Week Low3.68
- 52 Week Low Date07/01/25
Latest On 4D Molecular Therapeutics Inc
Key Stats
- Market Cap498.193M
- Shares Out52.28M
- 10 Day Average Volume0.88M
- Dividend-
- Dividend Yield-
- Beta2.76
Latest On 4D Molecular Therapeutics Inc
KEY STATS
- Open9.28
- Day High9.66
- Day Low8.97
- Prev Close9.53
- 52 Week High12.34
- 52 Week High Date10/28/25
- 52 Week Low3.68
- 52 Week Low Date07/01/25
- Market Cap498.193M
- Shares Out52.28M
- 10 Day Average Volume0.88M
- Dividend-
- Dividend Yield-
- Beta2.76
RATIOS/PROFITABILITY
- EPS (TTM)-2.70
- P/E (TTM)-3.53
- Fwd P/E (NTM)-3.13
- EBITDA (TTM)-174.346M
- ROE (TTM)-34.92%
- Revenue (TTM)88.242M
- Gross Margin (TTM)-
- Net Margin (TTM)-182.34%
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/10/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MORE4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with...
John Milligan Ph.D.
Executive Chairman of the Board
David Kirn M.D.
President, Chief Executive Officer, Co-Founder, Director
Kristian Humer
Chief Financial Officer and Principal Financial Officer
Address
5858 Horton Street #455, Emeryville
Emeryville, CA
94608
United States